dapsone

(redirected from Aczone)
Also found in: Dictionary, Thesaurus, Encyclopedia.

dapsone

 [dap´sōn]
an antibacterial used in treatment of leprosy and dermatitis herpetiformis and for prophylaxis of malaria caused by Plasmodium falciparum. Called also DDS.

dap·sone

(dap'sōn),
An antibiotic used to treat leprosy and certain cutaneous diseases such as dermatitis herpetiformis, is active against the tubercle bacillus, is used in the treatment of bovine coccidiosis and streptococcal mastitis, and is used as a second-line agent in Pneumocystis jiroveci [carinii] pneumonia.

dapsone

(dăp′sōn′, -zōn′)
n.
A sulfone drug, C12H12N2O2S, that is used primarily to treat leprosy and some forms of dermatitis.

dap·sone

(dap'sōn)
An antibiotic used to treat leprosy and cutaneous diseases such as dermatitis herpetiformis; active against the tubercle bacillus; used in the treatment of bovine coccidiosis and streptococcal mastitis and as a second-line agent in Pneumocystis jiroveci [carinii] pneumonia.

dapsone

Diaminodiphenyl sulfone. For many years this has been the standard drug to treat leprosy, but irregular use has led to the development of drug resistance. Dapsone is also used in the treatment of DERMATITIS HERPETIFORMIS which may be associated with COELIAC DISEASE.

dap·sone

(dap'sōn)
Antibiotic used to treat leprosy; active against the tubercle bacillus; used as a second-line agent in Pneumocystis jiroveci (carinii) pneumonia.
References in periodicals archive ?
Under the company's clinical trials of ACZONE Gel, 7.5%, the safety and efficacy were assessed in two identically designed, randomized, multi-centered, double-blind, vehicle-controlled 12-week studies.
According to the company, ACZONE Gel, 7.5% was approved based on co-primary endpoints of the GAAS and lesion counts (20 to 50 inflammatory and 30 to 100 non-inflammatory lesions at baseline).
In conjunction, ACZONE Gel, 7.5% will be available in May 2016 nationwide, concluded the company.
* Special Considerations: Obtain levels of glucose 6-phosphate dehydrogenase (G6PD) before initiating therapy with Aczone gel.
* Comment: Efficacy was based on two clinical studies that compared Aczone Gel, 5% and vehicle in a total of 3,000 patients 12 years and older.
He is a consultant to Galderma, which markets MetroGel, but is not involved in the Aczone trials.
Speciality pharmaceutical company Valeant Pharmaceuticals International Inc (NYSE:VRX) (TSX:VRX.to) stated on Tuesday that the company has executed an agreement to license the Canadian rights to ACZONE (dapsone) Gel 5% for the treatment of acne vulgaris.
ACZONE Gel is a topical formulation of dapsone that is used to treat acne in patients 12 years of age and older.
"Aczone Gel 5% is the first new chemical entity approved by the FDA for the treatment of acne in several years and represents an important clinical advance in dermatology, with a robust safety and efficacy profile demonstrated in more than 3,000 patients," says Dr.
Aczone is indicated for the treatment of acne vulgaris in the United States and Canada in patients ages 12 and olden It is the only acne treatment harnessing dapsone in a topical formulation to provide a convenient and effective therapy, says a company spokesman.